RIBOMETRIX

Live / Applied — Second extension granted (statement of use) (as of 31 Oct 2025)

What this means for you

Not registered yet, but its 20 Nov 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
98278663
Mark type
Stylized text
Filed
20 Nov 2023
Published for opposition
24 Sept 2024
Attorney of record
Douglas R. Wolf

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders; pharmaceutical preparations comprised of small molecules in the nature of organic compounds that target RNA for use in medical treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders via the induction or inhibition of gene expression; pharmaceutical preparations comprised of small molecules in the nature of organic compounds that target RNA-binding proteins for use in medical treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders via the induction or inhibition of gene expression; pharmaceutical preparations comprised of small molecules in the nature of organic compounds that target RNA and RNA-binding proteins for use in medical treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders via the induction or inhibition of gene expression; pharmaceutical preparations that contain small molecule therapeutics that target RNA for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders; pharmaceutical preparations that contain small molecule therapeutics that target RNA-binding proteins for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders; pharmaceutical preparations that contain small molecule therapeutics that target RNA and RNA-binding proteins for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, infectious diseases, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders

Owner

Prosecution history

  • 01 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 31 Oct 2025 — SOU EXTENSION 2 GRANTED
  • 31 Oct 2025 — SOU EXTENSION 2 FILED
  • 31 Oct 2025 — SOU TEAS EXTENSION RECEIVED
  • 22 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 21 Apr 2025 — SOU EXTENSION 1 GRANTED
  • 21 Apr 2025 — SOU EXTENSION 1 FILED
  • 21 Apr 2025 — SOU TEAS EXTENSION RECEIVED
  • 11 Feb 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 11 Feb 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
  • 11 Feb 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
  • 19 Nov 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 24 Sept 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 24 Sept 2024 — PUBLISHED FOR OPPOSITION
  • 04 Sept 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

View this trademark record on Marksy